In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months.
Publication
, Journal Article
St Clair, EW
Published in: Ann Intern Med
September 18, 2018
Duke Scholars
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
September 18, 2018
Volume
169
Issue
6
Start / End Page
JC33
Location
United States
Related Subject Headings
- Rituximab
- Recurrence
- Humans
- General & Internal Medicine
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- 3202 Clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
St Clair, E. W. (2018). In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months. Ann Intern Med, 169(6), JC33. https://doi.org/10.7326/ACPJC-2018-169-6-033
St Clair, E William. “In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months.” Ann Intern Med 169, no. 6 (September 18, 2018): JC33. https://doi.org/10.7326/ACPJC-2018-169-6-033.
St Clair EW. In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months. Ann Intern Med. 2018 Sep 18;169(6):JC33.
St Clair, E. William. “In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months.” Ann Intern Med, vol. 169, no. 6, Sept. 2018, p. JC33. Pubmed, doi:10.7326/ACPJC-2018-169-6-033.
St Clair EW. In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months. Ann Intern Med. 2018 Sep 18;169(6):JC33.
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
September 18, 2018
Volume
169
Issue
6
Start / End Page
JC33
Location
United States
Related Subject Headings
- Rituximab
- Recurrence
- Humans
- General & Internal Medicine
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- 3202 Clinical sciences
- 11 Medical and Health Sciences